Biogen Inc (NASDAQ:BIIB) EVP Alfred Sandrock sold 743 shares of the company’s stock in a transaction that occurred on Tuesday, February 20th. The shares were sold at an average price of $292.00, for a total value of $216,956.00. Following the sale, the executive vice president now owns 6,553 shares in the company, valued at approximately $1,913,476. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.
Alfred Sandrock also recently made the following trade(s):
- On Thursday, February 15th, Alfred Sandrock sold 1,294 shares of Biogen stock. The shares were sold at an average price of $298.85, for a total value of $386,711.90.
Shares of Biogen Inc (NASDAQ:BIIB) traded down $1.35 during mid-day trading on Wednesday, reaching $286.10. The company had a trading volume of 1,918,978 shares, compared to its average volume of 1,590,959. Biogen Inc has a 1-year low of $244.28 and a 1-year high of $370.57. The company has a market cap of $60,530.00, a price-to-earnings ratio of 16.39, a price-to-earnings-growth ratio of 1.52 and a beta of 0.75. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.34 and a quick ratio of 2.07.
Biogen (NASDAQ:BIIB) last issued its quarterly earnings data on Thursday, January 25th. The biotechnology company reported $5.26 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $5.44 by ($0.18). Biogen had a return on equity of 38.32% and a net margin of 20.69%. The business had revenue of $3.31 billion during the quarter, compared to the consensus estimate of $3.08 billion. During the same period last year, the company earned $5.04 earnings per share. The business’s quarterly revenue was up 15.1% compared to the same quarter last year. sell-side analysts forecast that Biogen Inc will post 24.88 EPS for the current fiscal year.
Several brokerages have issued reports on BIIB. Argus cut Biogen from a “buy” rating to a “hold” rating in a research note on Friday, February 16th. Canaccord Genuity set a $350.00 target price on Biogen and gave the company a “hold” rating in a report on Thursday, February 15th. William Blair reaffirmed a “buy” rating on shares of Biogen in a report on Thursday, February 15th. BidaskClub lowered Biogen from a “buy” rating to a “hold” rating in a report on Thursday, February 15th. Finally, Credit Suisse Group raised Biogen to a “buy” rating and set a $384.00 target price for the company in a report on Wednesday, February 7th. Ten analysts have rated the stock with a hold rating and twenty-three have issued a buy rating to the stock. Biogen has an average rating of “Buy” and an average price target of $368.99.
A number of hedge funds have recently modified their holdings of BIIB. Alliancebernstein L.P. grew its holdings in Biogen by 27.0% in the 4th quarter. Alliancebernstein L.P. now owns 3,414,672 shares of the biotechnology company’s stock worth $1,087,812,000 after buying an additional 727,007 shares in the last quarter. Ameriprise Financial Inc. grew its holdings in Biogen by 35.1% in the 3rd quarter. Ameriprise Financial Inc. now owns 2,309,394 shares of the biotechnology company’s stock worth $723,142,000 after buying an additional 600,384 shares in the last quarter. Bank of New York Mellon Corp grew its holdings in Biogen by 24.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 2,325,987 shares of the biotechnology company’s stock worth $728,314,000 after buying an additional 450,207 shares in the last quarter. Amundi Pioneer Asset Management Inc. boosted its stake in Biogen by 426.5% during the 4th quarter. Amundi Pioneer Asset Management Inc. now owns 245,830 shares of the biotechnology company’s stock valued at $78,314,000 after purchasing an additional 199,140 shares in the last quarter. Finally, Jackson Square Partners LLC boosted its stake in Biogen by 9.3% during the 3rd quarter. Jackson Square Partners LLC now owns 2,249,253 shares of the biotechnology company’s stock valued at $704,286,000 after purchasing an additional 191,526 shares in the last quarter. 89.20% of the stock is owned by institutional investors and hedge funds.
TRADEMARK VIOLATION NOTICE: “Biogen Inc (BIIB) EVP Sells $216,956.00 in Stock” was posted by The Lincolnian Online and is the property of of The Lincolnian Online. If you are reading this piece on another site, it was illegally stolen and reposted in violation of US & international trademark and copyright laws. The original version of this piece can be read at https://www.thelincolnianonline.com/2018/02/21/biogen-inc-biib-evp-sells-216956-00-in-stock.html.
Biogen Company Profile
Biogen Inc is a biopharmaceutical company. The Company focuses on discovering, developing, manufacturing and delivering therapies to people living with serious neurological, rare and autoimmune diseases. The Company markets products, including TECFIDERA, AVONEX, PLEGRIDY, TYSABRI, ZINBRYTA and FAMPYRA for multiple sclerosis (MS), FUMADERM for the treatment of severe plaque psoriasis and SPINRAZA for the treatment of spinal muscular atrophy (SMA).
Receive News & Ratings for Biogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biogen and related companies with MarketBeat.com's FREE daily email newsletter.